Medsider: Learn from Medtech and Healthtech Founders and CEOs
Regulatory Rigor as a Competitive Moat: Interview with Osteoboost CEO Laura Yecies
Laura Yecies, CEO of Osteoboost, shares insights on leveraging regulatory rigor as a competitive moat. The discussion covers the benefits of a Class II prescription path for their FDA-cleared osteopenia treatment, designing for user experience, and using early patient demand to…